Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
nephrotic syndrome 1 nephrologydiseases
paricalcitol 8 nephrologydiseasesdrugs
sodium bicarbonate 1 nephrologydiseasesdrugs
chlorothiazide 1 nephrologydiseasesdrugs
chronic kidney disease 10 nephrologydiseases
hydrochlorothiazide 1 nephrologydiseasesdrugs
kidney failure 2 nephrologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
chlorothiazide 42857 density lipoprotein; * VLDL very low density lipoprotein, TG Triglyceride; * PO4 phosphate; * HCT hydro chlorothiazide ; * MUAC Mid Upper Arm Circumference; * TSF Triceps Skinfold Thickness; * MUAMC Mid Upper Arm Muscle
hydrochlorothiazide 42852 low density lipoprotein; * VLDL very low density lipoprotein, TG Triglyceride; * PO4 phosphate; * HCT hydrochlorothiazide ; * MUAC Mid Upper Arm Circumference; * TSF Triceps Skinfold Thickness; * MUAMC Mid Upper Arm Muscle
paricalcitol 23122 studiesFishbane [[34]]RCT (double blind, 6 monthsn = 61 Pre-dialysis (Stages 1–4). Intervention: oral paricalcitol , 1 μg/day Control: placeboBiochemistry (mean spot urinary protein-creatinine ratio, serum intact PTH,
paricalcitol 23327 intact PTH, serum calcium, serum phosphorus, urine creatinine)Significant decrease in proteinuria in paricalcitol group. Mean spot urinary protein-creatinine ratios were +2.9% in controls and −17.6% in the intervention
paricalcitol 23536 intervention group (p = 0.04). Serum iPTH ↓significantly in intervention group (p = 0.01). 57.6% of paricalcitol group had a more than 10% decline in proteinuria. Modest effect size noted as is small study size.IIAgarwal
paricalcitol 23773 (double blind, 24 weeksn = 220 Pre-dialysis (Stage 3–4) Secondary hyperparathyroidismIntervention: oral paricalcitol 9.5 μg/week Control: placeboProteinuria51% intervention group compared to 25% control reduced proteinuria
paricalcitol 55222 an increased risk of cardiovascular events but not long term mortality [[36]]. The effects of oral paricalcitol supplementation on biochemical markers (including proteinuria) have been studied in both pre-dialysis
paricalcitol 55464 (Stages 1–4). A small, six month randomized controlled trial (RCT) found a modest effect size of oral paricalcitol supplementation of 1 μg/day vs. placebo, with the intervention group demonstrating a 17.6% decrease
paricalcitol 55765 [[34]]. It was also noted in this study that serum iPTH fell significantly amongst those who received paricalcitol supplementation (p = 0.01) [[34]]. Agarwal et al. similarly found that oral paricalcitol supplementation
paricalcitol 55854 who received paricalcitol supplementation (p = 0.01) [[34]]. Agarwal et al. similarly found that oral paricalcitol supplementation (mean dose 9.5 μg/week) was significantly associated with 51% vs. 25% (p = 0.004) reduction
sodium bicarbonate 51150 vegetables, as these appear to reduce blood pressure and have renoprotective effects comparable to sodium bicarbonate .2CMediterranean diet—we suggest adults with CKD consume a Mediterranean style diet to reduce dyslipidemia
Select Disease Character Offset Disease Term Instance
chronic kidney disease 1063 “What is the appropriate nutrition prescription to achieve positive outcomes in adult patients with chronic kidney disease ?” Databases included in the search were Medline and CINAHL using EBSCOhost search engine, Embase and
chronic kidney disease 4284 “What is the appropriate nutrition prescription to achieve positive outcomes in adult patients with chronic kidney disease ?”2. MethodsA systematic literature review of studies was designed to answer the clinical question.
chronic kidney disease 4758 “nutrition intervention” and for Cochrane “kidney failure, chronic”. M-tree headings in EMBASE were “ chronic kidney disease ” AND “diet therapy” and further derivatives of diet therapy such as protein, phosphate. Results
chronic kidney disease 5932 ERA/EDTNA European Best Practice Guideline on Nutrition, 2007 [[10]],Guidelines for the management of chronic kidney disease by the Canadian Medical Association, 2008 [[11]],Diagnosis and management of chronic kidney disease:
chronic kidney disease 6032 chronic kidney disease by the Canadian Medical Association, 2008 [[11]],Diagnosis and management of chronic kidney disease : A national clinical guideline by the Scottish Intercollegiate Guidelines Network, 2008 [[12]],National
chronic kidney disease 11872 [[30]].nutrients-06-00416-t001_Table 1Table 1Systematic reviews of nutrition interventions in patients with chronic kidney disease (CKD).AuthorNumber of StudiesSampleOutcome MeasuresResultsConclusionsLevel of Evidence [[20]]Protein
chronic kidney disease 50575 overweight (BMI 25.0–29.9 kg/m2) people should be encouraged to reduce their BMI to lower their risk of chronic kidney disease and end-stage renal disease.DMaintenance of a health body weight (BMI 18.5–24.9 kg/m2; waistcircumference
chronic kidney disease 52282 indicated.Conservative managementCMA (2008) [[11]]Renal programs and care providers for patients with progressive chronic kidney disease who choose not to pursue renal replacement therapies should ensure patients have access to an interdisciplinary
chronic kidney disease 52475 patients have access to an interdisciplinary team to provide comprehensive conservative management.All chronic kidney disease programs and care providers should have a mechanism by which to develop documents and processes for
chronic kidney disease 68848 status. The collaborative effort to use a global approach to international guidance in management of chronic kidney disease is welcome. While more evidence based studies are warranted, the customary nutrition prescription remains
kidney failure 4594 engine, Embase and the Cochrane Database of Systematic Reviews. MeSH terms for Medline and CINAHL were “ kidney failure , chronic” AND “diet therapy” OR “nutrition intervention” and for Cochrane “kidney failure,
kidney failure 4696 “kidney failure, chronic” AND “diet therapy” OR “nutrition intervention” and for Cochrane “ kidney failure , chronic”. M-tree headings in EMBASE were “chronic kidney disease” AND “diet therapy” and
nephrotic syndrome 5514 studies included where relevant. Nutritional management of acute renal disease, transplantation and nephrotic syndrome were not included in this review.In addition to this systematic literature search, hand searches of

You must be authorized to submit a review.